Biogen Consolidates Global Rights to Felzartamab with $850M Deal for China Market
Event summary
- Biogen acquires exclusive rights to felzartamab in Greater China from TJ Biopharma for $100M upfront, with up to $750M in potential milestone payments.
- Deal consolidates global rights to felzartamab under Biogen, following its acquisition of HI-Bio in July 2024.
- Felzartamab is a CD38-directed antibody being evaluated in Phase 3 trials for multiple immune-mediated diseases.
- TJ Biopharma will receive royalties on potential net sales in the Greater China Region.
The big picture
Biogen’s acquisition of felzartamab rights in Greater China underscores its strategy to expand its immunology portfolio in key global markets. The deal follows Biogen’s acquisition of HI-Bio in 2024, consolidating worldwide rights to the CD38-directed antibody. Felzartamab’s potential applicability across multiple immune-mediated diseases positions Biogen to capitalize on the growing demand for innovative treatments in China, a market with significant unmet needs in nephrology and oncology.
What we're watching
- Regulatory Approval
- The pace at which China’s National Medical Products Administration reviews the BLA for felzartamab in multiple myeloma.
- Market Penetration
- Whether Biogen can effectively commercialize felzartamab in the Greater China Region, given the large patient populations for IgAN and PMN.
- Pipeline Development
- How Biogen’s consolidation of global rights to felzartamab will impact its broader immunology pipeline and strategic focus.
Related topics